CGRP mAb Iv denied for missing prior authorization by Humana?

Humana's specific coverage criteria for cgrp mab iv are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Your IV CGRP Monoclonal Antibody — Prior Authorization Required

Humana requires advance prior authorization before it will cover intravenous CGRP monoclonal antibodies. This class of drugs — used for migraine prevention — is consistently subject to prior-auth requirements across most major insurers because of cost and because the clinical criteria (confirmed diagnosis, prior preventive treatment failure, prescriber type) need to be verified before dispensing. A "prior authorization required" denial is a procedural denial, not a clinical rejection — and it is among the most commonly reversed denial types when the right documentation is submitted.

## Why This Denial Is Appealable

If prior authorization was not obtained before infusion or dispensing, the appeal must argue either that (a) prior auth was sought and improperly denied or not processed, (b) the situation was urgent and retroactive authorization is warranted, or (c) the prior-auth criteria are in fact met and should be approved retroactively. If prior auth was sought but supporting documentation was incomplete, the appeal is an opportunity to submit a complete package that satisfies every criterion in Humana's published policy.

## Federal Appeal Framework

• Internal appeal: File under ACA §2719 / ERISA §503 within the deadline shown on your denial letter. Clearly state whether you are appealing a retroactive denial or a prospective prior-auth denial.
• Retroactive authorization request: If services were already rendered, ask your prescribing neurologist or infusion center to submit a retroactive prior-authorization request concurrently with the appeal.
• External review: If Humana upholds the denial, escalate to independent external review within approximately four months of the final internal denial.
• Expedited review: Available if the next scheduled infusion is imminent or if delay poses a clinical risk; document your migraine burden and scheduled infusion date.

## Documentation to Gather

1. Humana prior-auth criteria — obtain the current published prior-authorization requirements for CGRP mAbs from Humana's provider portal or by calling Provider Services. Use this as your appeal checklist. 2. Diagnosis confirmation — neurologist or treating physician chart notes confirming migraine diagnosis, type, and frequency as documented in the chart. 3. Prior preventive treatment history — for each prior preventive agent: drug name, start and stop dates as in the chart, and documented outcome (inadequate efficacy or intolerance). This is typically the central prior-auth criterion. 4. Prescriber medical-necessity letter — a structured letter from the neurologist addressing each Humana prior-auth criterion in sequence, citing specific chart dates. 5. Infusion or dispensing records — if services were already rendered, include the infusion center's records (date of service, drug administered, provider) to support retroactive authorization. 6. Any prior authorization reference number — if an auth was submitted and not properly processed, include the reference number and submission date.

## Criteria-Mapping Structure

| Humana Prior-Auth Criterion | Satisfying Documentation | |---|---| | Confirmed migraine diagnosis | [Neurologist note, date, diagnosis] | | Required prior preventive therapies tried and failed | [Drug name, dates, documented outcome — one row per drug] | | Prescriber is appropriate provider type | [Name, specialty, NPI] | | Drug and formulation match covered indication | [FDA label indication vs. chart diagnosis] | | Any frequency/quantity criteria | [Prescribed regimen vs. policy allowance] |

Submit the completed table with all supporting records so Humana's reviewer can approve in a single pass.